Quick Answer
China SXT Pharmaceuticals, Inc. reported Stockholders Equity of $15.44 million for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $15.44M | +10.8% |
| 2024 | $13.93M | -5.2% |
| 2023 | $14.69M | -8.7% |
| 2022 | $16.08M | +0.8% |
| 2021 | $15.96M | +69.8% |
| 2020 | $9.40M | -15.4% |
| 2019 | $11.11M | +238.1% |
| 2018 | $3.29M | +77.4% |
| 2017 | $1.85M | +149.4% |
| 2016 | $742.8K | — |
- China SXT Pharmaceuticals, Inc. showed an increase of +10.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, China SXT Pharmaceuticals, Inc.’s stockholders equity has grown by 1978.7% (from $742.8 thousand to $15.44 million).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: